Article Text

PDF
FRI0175 Two-Year Retention Rate of Golimumab for Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis: A Retrospective Analysis of The Italian Lorhen Registry
  1. M. Manara1,
  2. E.G. Favalli1,
  3. R. Caporali2,
  4. P. Sarzi Puttini3,
  5. A. Marchesoni1,
  6. L. Sinigaglia1
  1. 1Rheumatology, Gaetano Pini Institute, Milan
  2. 2Rheumatology, University of Pavia, IRCCS Policlinico San Matteo Foundation, Pavia
  3. 3Rheumatology, University Hospital L. Sacco, Milan, Italy

Abstract

Background Golimumab (GLM), a subcutaneous TNF inhibitor, has been licensed for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS). Data from real-life registries on long term retention rates of GLM in these diseases are scarce.

Objectives To assess the 2-year retention rate of GLM in RA, PsA and AS patients from a multicentre observational cohort (the LORHEN registry).

Methods We performed a retrospective analysis of data from all patients with RA, PsA and AS included in the LORHEN registry who started GLM from October 2010 to September 2015. Only patients with at least one reported visit of follow-up were included. The 2-year retention rate was calculated by Kaplan-Meier method for each disease. The risk of discontinuation between patients who received GLM as first- or second-line biotherapy was compared by a stratified log-rank test.

Results Overall 410 subjects were included in the analysis: 180 patients with RA, 110 with PsA and 120 with AS.

RA patients had a mean (Standard Deviation, SD) age of 54,6 (13,6) years and a mean (SD) disease duration of 9,5 (9,3) years; most of them were female (81,6%). Among them, 79 patients stopped the treatment with GLM due to inefficacy or adverse events before 24 months of treatment; the overall 2-year retention rate was 48%. GLM was given as first and second line treatment in 85 and 51 patients, with a 2-year retention rate of 49% and 53%, respectively; the comparison between first and second line treatment groups did not show any significant difference in mean survival time (p=0.724).

Among PsA patients, 50% were male, with a mean (SD) age of 47,9 (12,8) years and a mean (SD) disease duration of 7,9 (6,7) years. Among them, 42 patients stopped the treatment with GLM due to inefficacy or adverse events before 24 months of treatment; the overall 2-year retention rate was 48%. GLM was given as first and second line treatment in 47 and 30 patients, with a 2-year retention rate of 66% and 54%, respectively; the comparison between first and second line treatment groups did not show any significant difference (p=0.333).

SA patients had a mean (Standard Deviation, SD) age of 45,2 (12,2) years and a mean (SD) disease duration of 9,7 (10) years; 56,7% of patients were male. Among them, 33 patients stopped the treatment with GLM due to inefficacy or adverse events before 24 months of treatment; the overall 2-year retention rate was 65%. GLM was given as first and second line treatment in 51 and 42 patients, and the 2-year retention rate was of 57% and 76%, respectively; the comparison between first and second line treatment groups did not show any significant difference (p=0.127).

Conclusions GLM showed a similar 2-year retention rate in first and second line treatment of patients with RA, PsA and SA in real-world data from the LORHEN registry. The 2-year retention rate was higher in SA patients than in RA and PsA patients.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.